Evaluation of covariates using population pharmacokinetics approach for dose individualization of levothyroxine in patients with post thyroidectomy and 131I ablation therapy Dr Kumar Rajesh1, Dr Prabhu Mukhyaprana2, Dr Pai Sreedhar R3, Mr. Shenoy Vasudev4,* 1Dept of Nuclear Medicine, Kasturba Medical College, Manipal University, India 2Dept of Medicine, Kasturba Medical College, Manipal University, India 3Dept of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University, India 4Biovailability/Bioequivalence and PK Unit, Ecron Acunova, Manipal, India *Corresponding Author E-mail: Shenoy.vasudev@gmail.com
Online published on 21 August, 2018. Abstract The current therapy for patients with thyroid cancer is total or near to total thyroidectomy with Radio Iodine treatment. Subsequent to the thyroidectomy the patients are on Levothyroxine as a supplement therapy to maintain the Thyroid hormone levels. Levothyroxine has been considered as a narrow therapeutic index drug. In Thyroid cancer patients, radio-iodine ablation procedure causes hypothyroid state which will be further elongated by the administration of sub optimal doses and hyperthyroid symptoms with higher doses. The current study was conducted to evaluate the covariates influencing the drug concentration of levothyroxine in our target population, i.e Patient with Papillary carcinoma, undergone total thyroidectomy followed by 131I ablation and on Levothyroxine. Top Keywords Levothyroxine, Population Pharmacokinetics, Papillary carcinoma. Top |